The FDA has designated Matinas BioPharma’s (NYSEMKT:MTNB) MAT2203 a Qualified Infectious Disease Product for Fast Track review for the three new indications: the prevention of invasive fungal infections due to immunosuppressive therapy, treatment of invasive candidiasis and treatment of invasive aspergillus.
MAT2203 is a lipid crystal nanoparticle formulation of the broad spectrum anti-fungal agent Amphotericin B. Its value proposition is less side effects, particularly less renal toxicity, compared to currently available versions.
Shares are up 12% premarket on increased volume.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.